• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Amyloidosis

Amyloidosis - 258 Studies Found

Completed : Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
: Multiple Myeloma and Plasma Cell Neoplasm
: 2007-05-23
:
  • Biological: filgrastim No admi

Terminated : Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
:
  • Drug/Agent Toxicity by Tissue/Organ
  • Multiple Myeloma and Plasma Cell Neoplasm

: 2003-01-24
:
  • Biological: filgrastim
  • Drug: amifostine tr

Active, not recruiting : A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)
:
  • Light Chain (AL) Amyloidosis
  • Cardiac Involvement

: 2013-11-18
:
  • Drug: Epigallocatechin-3-gallate (EGCG)

Active, not recruiting : Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
: Multiple Myeloma
: 2004-01-09
:
  • Drug: filgrastim 16 mg/kg/day

Terminated : 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
:
  • Multiple Myeloma
  • Plasma Cell Neoplasm

: 2004-01-09
:
  • Biological: filgrastim 16mcg/k

Completed : Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
: Multiple Myeloma and Plasma Cell Neoplasm
: 2001-01-06
:
  • Biological: filgrastim
  • Biological: recombi

Withdrawn : Mixed Chimeric Transplantation for Primary Amyloidosis
:
: 2025-08-04
Active, not recruiting : Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
: Amyloidosis
: 2009-11-02
:
  • Drug: Bortezomib

Completed : Autologous Stem Cell Rescue for Primary Amyloidosis
:
  • Amyloidosis
  • Blood and Marrow Transplant (BMT)

: 2005-09-13
: Procedure: high dose chemo then auto hematopoietic cell transplant
Completed : Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
: Amyloidosis
: 2005-09-12
: Drug: CC-5013 40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.